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Antibiotic discovery has stagnated. To avoid catastrophe, it must speed up. One of the 
most heavily used methods of drug discovery is high-throughput screening, yet in the 40 years of 
use of high-throughput screening, zero antibiotics have come to market from this method. Recent 
advancements in deep learning have provided a potential solution to this problem. It has been 
demonstrated that with a clean yet relatively small training dataset, meaningful predictions can 
be made on large chemical libraries. However, relying on cherry-picked data with extremely 
confident ‘hits’ or ‘misses’ fails to represent the uncertainty of large real-world datasets. In this 
paper, I analyze the current state of HTS and propose and new workflow that is compatible with 
machine learning. The key to machine learning compatibility is determined to be the aversion of 
false negatives. More specifically, it is most important to reduce the ‘noise’ relative to the size of 
the dataset for maximum compatibility. Furthermore, using the standard tool ChemProp, I 
discern that the size of matters significantly, and small datasets of strong data will still fail to be 
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Hit  Prospective active molecule 
Miss  Prospective inactive molecule 
HTS  High Throughput Screening 
Fingerprinting  Generating a ‘fingerprint’ for molecules based on their molecular features 
Fingerprint The unique identity of a molecule, which can be plotted in a chemical space 
GNN  Graph Neural Network 
IC50 50% inhibitory concentration – the concentration of an antimicrobial agent 
required to inhibit 50% of the growth of a microbe 
MTb Mycobacterium Tuberculosis 




1.1 The Problem and Historical Context 
Continuous antibiotic discovery is undoubtedly a crucial process to maintain stability of 
society. Despite a significant negative societal impact if this process slows, little progress has 
been made in antibiotic discovery since the “Golden Age” of the 1940s-1970s. [1] Decreasing 
economic incentives to those who research antibiotics paired with hastening antibiotic resistance 
has made this a uniquely tough challenge. [2] On the forefront of this problem is academia – 
conducting large scale high-throughput screening campaings across the world. However, in 
nearly 40 years of high-throughput screening, not a single antibiotic has come to market from 
this method. [3] A solution is needed to reconcile these massive libraries of data and millions of 
man-hours – not only so that the research will not have been done in vain, but so directed 
screening campaigns can be much more efficient in the future. The solution proposed in this 
paper is a refined approach to antibiotic discovery building off of previous deep-learning 
research. 
 
1.1.1 The Dire Need for New Antibiotics 
The immediate societal effects of pandemic-scale mortality are now known by everyone, 
with the seeming irreversible changes that COVID-19 has brought. This is the scale of the 
problem that antibiotic resistance presents if a solution is not found. Current projections estimate 
that deaths from antibiotic resistant infections will reach over 10 million per year by 2050, 
placing mortality around that of cancer. Among the obvious moral obligation to prevent these 
deaths if possible, the economic impact is also extreme. This increase in mortality is estimated to 
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drop global GDP by 2-3.5%, just from the drop in the workforce. [4] Economic impacts will be 
much more extreme if COVID-19-esque prevention measures are taken, as 10 million deaths a 
year is roughly 4 times COVID’s mortality rate. 
To make matters worse, the economic incentives to discover antibiotics have been 
deficient and declining over time. There are too few drugs in development to address the range 
of antibiotic resistant infections, and it is inevitable that most of the drugs in development will be 
discontinued. Only 60% of drugs that get to Phase 3 are approved. Also, it generally costs over a 
billion dollars to get a single drug to market, yet 95% of antibiotics in development are being 
researched by small pharmaceutical companies. [2] This means that if there are not immediate 
positive results, and a top pharmaceutical company doesn’t invest, even promising antibiotics 
will have development discontinued. 
To address the problem of economic incentives and the FDA price barriers, the initial 
discovery phase must be made much cheaper, and the confidence of initial screening must be 
much higher. Using deep-learning and virtual screening is a very cost-effective solution, but 
historically, has fallen short in terms of accuracy. [5] Recent technological advancements, data 
science solutions, and a shift in screening methodology may be able to solve these shortcomings. 
 
1.1.2 Historical Approaches to Antibiotic Discovery 
There are 3 main historical eras of antibiotic discovery: the Golden Era, the Medicinal 
Chemistry Era, and the Resistance Era. [5] Despite the extreme success of antibiotic discovery 




1.1.2.1 The Golden Era (1929-1960s) 
The discovery of penicillin in 1929 ushered in an era of antibiotic discovery in natural 
products. Specifically, there would be screening of microbes in soil that produce secondary 
metabolites to prevent bacterial infections. This Golden Era of natural product discovery lead to 
the discovery of some of the most widely used antibiotics – the Beta-Lactams (penicillin), the 
Macrolides, Tetracyclines, and more. There was not an absence of synthetic antibiotics from this 
time, however, characterized by the Sulfa- drugs (1932), Oxazolidinones (1955), and Quinolones 
(1961).  [6] This era was ended for two reasons: 1) These drugs had significant toxicological 
drawbacks due to the lack of human design, and 2) Resistance due to horizontal gene transfer 
happened rapidly. This second reason introduces a trend in the history of antibiotic discovery – 
adaptive resistance beats the discovery method and heralds a new era. [5] 
 
1.1.2.2 The Medicinal Era (1970s-1980s) 
The Medicinal Era began in the 1970s, as a response to the inefficiencies that came from 
discovery without design. So, researchers rode the coattails of the Golden Era discoveries and 
focused on design. There were very few novel ‘scaffolds’ discovered in this era, but there was a 
huge emphasis on using medicinal chemistry to take the natural molecular scaffolds discovered 
in the golden era and to improve upon them. This allowed for them to fix toxicological 
parameters, improve delivery and potency, and avoid resistance for another couple decades. 
However, the inevitable happened, and resistance caught up again and forced researchers to 




1.1.2.3 The Resistance Era (1990s – Present) 
The Resistance Era marks the mass adoption of high throughput screening. The 
innovation of high throughput synthesis and chemical handling robots allowed for large chemical 
libraries to be made and quickly screened. The technological revolution of accessible computers 
in this era allowed for extremely large datasets to be taken and handled.  [5] However, this is 
where the issue seems to lay. Since the advent of this era, no antibiotics have come to market 
from high throughput screening. The overall efficiency and success of screening is extremely 
low, despite unprecedented advances in technology. 
The problem becomes clearer when considering the scale of the chemical space in which 
high throughput screening attempts to discover drugs. Following a restrictive structural rule that 
tends to describe FDA-approved drugs, Lipinski’s Rule of 5, the amount of druggable molecules 
that can be screened is conservatively estimated to be 1060. [7] This is more than the number of 
stars in the universe, squared.  
Historically, evolution has been able to navigate this space by randomly trying different 
molecules for millions of years and only keeping what works. Now, we have reached the limits 
of natural product screening, so we try to navigate this incomprehensibly big space manually. 
‘Manually’, in this context, means ‘in a reasonable amount of time’. Given this scale, it is very 
evident why these irrational brute-force screening efforts have failed. Rational drug discovery 
must be paired with irrational (brute force HTS) drug discovery if we want a chance at gaining 





1.2 The State of Research 
Neural networks are the ideal tool for virtual screening for a variety of reasons. The 
efficacy is best demonstrated in the flagship paper by Stokes et. al in 2019, A Deep Learning 
Approach to Antibiotic Discovery. Specifically, the researchers trained a new generation of deep 
neural networks called graph neural networks (GNNs), which were released the year prior in a 
package called ChemProp. [8] They were able to screen the Drug Repurposing Hub and discover 
a novel antibiotic. Since being released in 2020, it has been cited over 300 times. This paper 
undoubtedly caused excitement, but the methods and data they used differ from the real-world 
high throughput screening situation in a few key ways. In the following sections, current GNN 
models are explained, and key issues are highlighted in regards to the useability of the software 
on real world data. 
 
1.2.1 Graph Neural Networks 
ChemProp uses Message Passing Neural Networks (MPNNs) – a type of GNN. First of 
all, graphs are a type of data structure in which you have nodes (vertices) and many connections 
(edges) between individual nodes. GNNs use the graph data structure. Each node integrates data 
from neighboring nodes until the final layer is reached, and a classification is determined. In 
ChemProp, MPNNs with graphs that have atoms as vertices and bonds as edges are used. 
MPNNs work in two phases. First, the ‘message passing phase’ transmits information across the 
molecule to build a neural representation of the molecule of interest. Second, there is a ‘readout 
phase’, in which predictions are made for the molecular property of interest using the built neural 
representation. [8] Creating a neural representation of the graph of the molecule rather than using 
fixed molecular descriptors (i.e., fingerprints) has proven to be uniquely effective in classifying 
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drugs. [3] Again, however, the MPNNs used still use a type of pseudo-fingerprinting method. 
Specifically, the models in question will use atom features (i.e. atom type, # of bonds, etc.)  or 
bond features (i.e. bond type, stereochemistry, etc.) as information to pass along the network. 
The weight of individual features is set manually, and which features are used is artificially 
determined. This needs to be done in some fashion, as one cannot get a perfect representation of 
large molecules with a reasonable amount of computing power. However, this is important to 
take into consideration when considering chemical space, as described in the following section. 
 
1.2.2 Chemical Space 
Chemical space is the set of all possible stable molecules. Representations of chemical 
space are n-dimensional and grouped based on molecular features. When using different 
molecular features as dimensions in plotting chemical space, different spatial relationships can 
arise. 
An intuitive way to think about how these neural networks classify molecules is thinking 
about the chemical space that the molecules inhabit. When the neural network is trained, it 
‘knows’ certain structural parameters – the atom or bond features in MPNNs. The different atom 
or bond features serve as the dimensions of the chemical space that the neural network can see. 
The neural network eventually discovers a structural motif that is correlated with the desired 
classification (i.e. antibacterial activity). In this chemical space, since the motif is conserved 
among hits, the hits would be located near each other spatially.  
In order for the neural network to predict activity based on a structural motif, the 
structural motif must be present (or nearly present) in the training data. Because of this, Stokes 
et. al [3] made sure that the chemical space of the training data and the library they predicted on 
were similar. They used t-SNE, an n-dimensional data visualization method, to plot the library 
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they predicted on. Then, they picked an evenly distributed sample of chemicals in the same area 
of space to order and test. This was their training data. The best antibiotic discovered was found 
at an arbitrary location in this space.  
This creates a key issue. In the many decades of high-throughput screening, there hasn’t 
been as much special attention to sampling portions of chemical space that are similar to libraries 
available to predict on. Many labs end up with data that resides in a small, yet nicely distributed, 
section of chemical space. A neural network will struggle to make prediction on chemicals 
outside of this space, as it does not have the information required to make good predictions. 
Another consideration to keep in mind is that the ways that methods of plotting chemical 
space yield different groupings. The MIT paper used t-SNE to plot their chemical space. 
Generally, the programs that plot with t-SNE have presets with a large amount of molecular 
parameters (dimensions). However, the neural network sees a chemical space based on its own 
molecular parameters. For best results, the data visualization method that decides the chemicals 
to train with should use the same fingerprinting method as the neural network.  
The solutions I propose to these issues are: 
1. When ordering chemicals for HTS, consider large libraries available to predict on, 
and purchase from a chemical space comparable to larger libraries. 
2. Determine the training set’s spatial similarity to the prediction libraries based on the 
molecular fingerprints that your neural network sees – not an arbitrary one. 
3. When trying to reconcile data that isn’t evenly distributed across a large chemical 
space, only predict on chemicals that reside in and around a similar chemical space as 
the training library. Otherwise, the predictions will have little correlation to reality 




1.2.3 Data Quality 
There are massive issues with the quality of data in most high-throughput screening 
operations. There are many sources for error in data – from heat inconsistencies based on the 
well position on a plate that change the growth of a culture without any drug intervention, to 
experimental error associated with individual assays. Multiple screening campaigns and with the 
same and different assays have been shown to give wildly different results.  
The issue of data quality in existing data is more easily addressed for hits than misses. In 
a screening campaign, the noisiest data is the initial screen. Then, the most promising candidates 
from the initial screen are re-tested and validated against possible assay experimental error. The 
next step for antibiotic discovery is to take the subsequent best candidates and generate IC50 
curves. The IC50 curves are very confident, as the binary ‘hit’ or ‘miss’ value is determined from 
many datapoints rather than a single one. So, we can be confident that the existing hits are indeed 
hits. However, we can not be confident in the misses. The initial screening campaign is very 
noisy. There could be thousands of hits that came up as misses. If this error is significant enough, 
it will hurt the accuracy of the model in practice and may decouple the measures of accuracy of 
the model from its true accuracy. For example, precision recall curves (PRC) are used to judge 
the accuracy of a model. The model will predict on itself, and if the prediction aligns with the 
training data, it will be a ‘true positive’ or ‘true negative’. If the prediction doesn’t align with the 
training data, it will be a ‘false positive’ or ‘false negative’. The area under the PRC (the PRC-
AUC) then can give you a score based on the ratios of true/false positives/negatives to give you a 
measure of the accuracy of the model. Since certain misses may really be hits, even if the model 
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is trained well, it will create more ‘true negatives’ than there are in reality. This means that even 
the scores of accuracy themselves will become inaccurate. 
The solution to this is to create IC50 curves for both types of molecules – misses and hits 
– and to only train the neural network on molecules that you have IC50 data on. If you rely on 
any data from an initial screening campaign, the noise will significantly hurt the model. This 
makes screening harder and more expensive in the short term but gives you the power to predict 
on much larger groups of molecules than otherwise possible. 
 
1.3 The New Workflow 
Based on the previous arguments about the current state of high-throughput screening and 
data quality, a new workflow can be constructed that is compatible with in-silico tools.  
 
1.3.1 The Traditional HTS Workflow 
The traditional high-throughput screening workflow is summarized in Figure 1 below. It 
begins with some type of virtual screening for compound selection. This essentially comes from 
a guess by the scientist. They will determine an interesting region of chemical space that may 
have certain molecular properties they think may be active, or simply choose an unexplored 
region of chemical space arbitrarily. They end up choosing a very narrow region of chemical 
space, which does not give useful information for the machine learning model. The machine 
learning model can only predict accurately on the chemical space neighbors of the tested 
molecules – the less similar the testing library is to the screening library, the lower the efficacy. 
So, from the first step, it is incompatible with machine learning.  
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The second step is the actual screening. In the traditional workflow, researchers do an 
initial screening and then select the ‘hits’ from the screening. Then, they do a secondary 
screening and rescreen the ‘hits’ to preliminarily validate the screening and select the best among 
the hits for further testing. This leads to a restricted, hit-biased selection of chemicals 
represented in the data. A machine learning compatible workflow must have equal confidence in 
hits and misses. 
The final step in the traditional workflow is validation. Generally, the researcher validates 
the hit data with a calculated value. For example, an IC50 curve gathers datapoints of inhibition 
at different concentrations, and the concentration of 50% inhibition is calculated. This gives less 
random error. This data is again useless for machine learning models, as you need to have 
confident misses as well. Hit bias continues to pose a large problem. 
Fig 1. Traditional HTS Workflow. This method has a low success rate, a low number of 




1.3.2 Machine-Learning Catered HTS Workflow 
The machine-learning catered HTS workflow is summarized in Figure 2 below. The first 
step is to consider the library that the researchers want to predict on, rather that what they want 
to screen. Once you determine this un-screened library via your data science tools of choice, 
researchers then can take a small, evenly distrusted sample representative of this chemical space 
– only a few thousand molecules. The larger the sample of chemical space you choose, however, 
the more molecules you will need to select for screening. Machine learning models find trends 
among structural motifs of the molecules and correlates them with a ‘hit’ or ‘miss’ tag, so the 
structural motifs of the chemicals in the prediction space must be somewhat represented in the 
training (screening) data. 
 Once your screening set is determined, the researcher screens once to determine hits and 
misses. Then, the researcher selects a sample rate of ‘hits’ vs ‘misses’ in accordance to the 
historical performance of the machine learning model – i.e., a specific model may perform better 
with a 4% hit rate than an 8% hit rate. This is learned over multiple trials. This gives the 
researcher a lot more control over the data. They now have a manual, configurable, non-hit-
biased selection criteria that can be adjusted to give better performance if the model 
underperforms. Another validation screening isn’t required, as the data should be accurate 
enough to move on to the IC50 curves and generate concrete data. 
 Finally, the researcher validates both hits and misses with calculated values such as IC50 
curves. This takes longer than the IC50 hit validation in the traditional workflow, since it’s 
testing at more chemicals by this stage. However, since the initial screening was much smaller 
and a second initial screening to re-test the hits did not need to happen, time is still saved. Then, 
the researcher trains the model and predicts on the prediction library. Then, they take the most 
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confident hits from the prediction library and use more in-silico methods to further discriminate 
them (toxicity-predicting neural networks, drugability predictions, etc.). Finally, they order these 
chemicals and test them empirically. 
 
Fig 2. HTS Workflow with In-Silico screening compatibility. There is a lower chance of 
false negatives with this workflow. Because of this, millions more compounds can be screened in 
a cheap and effective manner.  
 
1.3.2.1 How to Reconcile Old Data 
There is still 40 years of old HTS data that has not been able to create new antibiotics. 
The best way to reconcile this data is to do a variation of the new HTS workflow – one that is 
directed at re-screening the misses that are in the neighborhood in chemical space of the 
confident ‘hits’ that were previously discovered. So, the workflow is modified to be:  
1. Analyze the chemical space of the ‘hits’ 
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2. Choose the desired hit-miss ratio, and take the data for misses evenly distrusted 
across the space of the validated hits 
3. Validate (generate IC50 curves) the misses. 
4. Train the model and predict on the chemical space that the screening data resides in. 
Without any re-screening, the data is virtually useless. This is the most efficient way to make this 
data useful again – for target agnostic high-throughput screening. However, if the screening is 
for docking on a known protein target, there is software that can perform hit-enrichment and 
reconcile these datasets without father screening. An example of this software is GFScore. [9] 
Again, if the target is unknown, further screening is required. 
 
1.3.3 Workflow Discussion 
Overall, the newly proposed HTS workflow is much more cost and time effective. It is 
able to achieve an unprecedented throughput. The key component of the new workflow that 
allows compatibility is the lack of false negatives. The other differences are merely 
consequences of machine learning’s efficacy that can save time. 
The false negative consideration (and thus the workflow modification) is an analytical 
argument based on the metrics that are used to appraise the performance of neural networks and 
is trivial – better quality data will yield better results.  Regardless, in the following section, data 
with a higher chance of having false negatives is compared to confident data in order to assess 
what makes a ‘good quality’ dataset.  
This is the questions that can be answered in this thesis. With machine learning methods, 
how much does the size of the dataset matter? There are powerful machine learning tools – if 
very small training datasets with confident data are used, will they still be accurate?  Finally, is 
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using confident data demonstrably better than using noisy data with false negatives? These 







2.1 The Data 
A primary high-throughput screening campaign for activity against Mycobacterium 
Tuberculosis was performed by Jeremy Woods in mid to late 2019 in the Sacchettini laboratory 
at Texas A&M. The initial screening was done via two separate assays: a luciferase-based and a 
resazurin-based assay. The library screened is ‘SAC3’, a collection of 9976 molecules selected 
based on the potential for activity. After the best 960 hits [further used as 957, as 3 structural 
identifiers are missing] were identified (3 plates, 320 chemicals per plate), dose response assays 
for both luciferase and resazurin assays were performed and IC50 values were calculated.  
Relating to the previous sections, the IC50 values refer to the more confident values and 
the initial screening is less confident. However, the IC50 dataset is smaller. 
2.1.1 Primary Screening – Hit selection 
Two assay types were used. The first is the luciferin-luciferase gene reporting complex. 
The luciferase gene, when transfected into MTb, produces luciferase, an enzyme that acts on the 
luminescent protein luciferin. If the MTb survives, luminescence continues to occur. Error may 
come if the chemical inhibits gene expression or if the chemical inhibits luciferase itself.  
The second type of assay used was a resazurin based assay. A resazurin assay relies on 
fluorescence rather than bioluminescence. In live MTb, resazurin is reduced to resorufin. 
Resorufin is fluorescent and can be detected by fluorescence spectroscopy. If the MTb dies, 
fluorescence stops. However, if the chemical interferes with the redox process there is error. 
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Another large source of error is ‘edge effects’. In the chemical plates, heating tends to be 
uneven based on the position of the plate in the incubator and the heat transfer of the plate itself. 
So, significant random error is introduced. 
Because of all these sources of error, data will be more accurate if the hits are selective 
comparatively across different assays. A boolean discrimination was used to generate two 
different datasets. One had a ~5% hit rate (z-score < 1.5 in luciferase and resazurin, 516/9976), 
and the other had around a ~9.5% hit rate (z-score < 0.5 in luciferase and resazurin, 936/9976). 
These datasets were both used to train Chemprop, and AUC was used as the metric to determine 
how well the model can classify the training molecules. 
 
2.1.2 IC50 Data – Hit selection 
This data is the ‘most confident’ data that the Sacchettini lab had produced, as multiple 
doses are tested and the IC50 is calculated. Around half of these molecules had no discernable 
activity (>40 µM IC50). A Boolean discrimination was used to match the hit rates with the larger 
datasets. For the ~5% hit rate, the best 50 out of 957 molecules had an IC50 of less than 1.5 µM 
in luciferase and resazurin. For the ~9.5% hit rate, the best 91 out of 957 molecules had an IC50 
of less than 3.5 µM in luciferase and resazurin. These datasets were both used to train Chemprop, 
and the AUC was recorded. 
 
2.1.3 Generation of Primary Screening Datasets for Comparison with IC50 Data 
Finally, two more training datasets were generated with 957 molecules each (50, 91 hits) 
to directly compare the IC50 data to the primary screening data. These datasets use the ‘hit’ or 
‘miss’ criteria of the primary screening rather than the IC50 data, yet all of the structures are the 
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same. So, this represents a small training set with data that has a high probability of having false 
negatives. This was used to train Chemprop, and the PRC-AUC was recorded. The details for the 






Table 1: Compatibility of Various Datasets with Chemprop 
Dataset PRC-AUC 
Large Primary Screening ~9.5% Hit rate 0.845 
Large Primary Screening ~5% Hit rate 0.807 
Small Primary Screening ~9.5% Hit rate 0.706 
Small Primary Screening ~5% Hit rate 0.489 
Small IC50 Screening ~9.5% Hit rate 0.722 
Small IC50 Screening ~5% Hit rate 0.521 
Table 1. The AUC measures the area under a PRC curve, which gives a metric of how well the machine learning 
model was able to classify the training data after being trained (closer to 1 is better). The ‘PRC curve’ is a plot 
comparing the ‘precision’ on the y axis to ‘recall’ on the x-axis as discrimination threshold is varied. These are 
defined as: precision = (true positives / true positives + false positives). recall = (true positives / true positives + 
false negatives). A good classifier will have a PRC-AUC of around 1, while a random classifier will have a PRC-
AUC close to 0.5. 
3.1.1 The Significance of Simple Data in Table 1 
The data in Table 1 is simple, yet extremely significant. The most significant thing to 
note is that having a higher hit rate resulted in a much better PRC-AUC. First, appears that this 
does not scale in a linear fashion relative to the size of the dataset, as the difference between the 
PRC-AUC in the larger datasets is much smaller than the difference in the smaller datasets. In 
practice, this means that having a higher hit rate may give a more accurate model overall and 
may lend more confidence in seeing some activity in the predicted hits. However, this also means 
that the hits that are confidently predicted may not be elite. Having a lower threshold for hits 
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may mean that you are training the model to create weak antibiotics. A sweet spot can be found 
by the researcher according to their individual needs. 
The second thing to note is the difference between the small IC50 datasets and the small 
primary screening datasets. There is a clear increase in the PRC-AUC for the IC50 datasets, 
showing that this specific method of validation aids the model in a significant way. The PRC-
AUC can be further enhanced by model-optimizing tools that likewise favor data with less noise, 
such as hyperparameter optimization.  
The final note to make is that there is a huge difference between the PRC-AUC of both 
small datasets and the larger dataset that has ‘noisy’ data. Despite the IC50 data being more 
confident and working with the model better, having a larger training dataset simply creates a 
better model. There is likely an upper limit to this, as you begin to approximate the ‘true’ 
configuration of the neural network eventually. 
3.1.2 Discussion – What does this tell us? 
Through consideration of Table 1’s data, it is evident that goal of any modified HTS 
workflow is to reduce as much noise as possible relative to the size of the dataset. A few false 
negatives will not affect a very large dataset, yet a few may affect a small one significantly. 
Likewise, having many false negatives or positives will harm any model you try to train. 
However, the model should not be perfect. Having some noise is natural. If the PRC-AUC is 1, 
and the model retroactively predicts every training molecule ‘perfectly’, it is likely to be an 




4.1 A Broad Spectrum Era 
Contrary to the literature [5], the new era of antibiotic discovery will not be a narrow-
spectrum era. Machine learning is the first tool to ever be able to traverse chemical space in a 
meaningful way. In configuring the workflow and model correctly, researchers are able to 
virtually screen millions of molecules within a day and tell how elite their antibiotic predictions 
may be. Because it’s now easy to quantify the strength of predicted antibiotics by minimizing the 
training set hit rate relative to the resulting AUC, this spectrum will be broad spectrum. With this 
new ability to test millions of chemicals in a target-agnostic fashion, there is no reason to believe 
that the future of antibiotics is target-specific. There is likely to be another ‘penicillin’ in the 
future, that can continue to delay the AMR infection doomsday. With strong tools such as 
machine learning, there is no reason not to be optimistic about the future. We just need to make 
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APPENDIX: DATASET INFORMATION 
Table A.1: Dataset Information 
Dataset Hits Misses Net Molecules 
Large Primary Screening ~9.5% Hit rate 936 9040 9976 
Large Primary Screening ~5% Hit rate 516 9460 9976 
Small Primary Screening ~9.5% Hit rate 91 866 957 
Small Primary Screening ~5% Hit rate 50 907 957 
Small IC50 Screening ~9.5% Hit rate 91 866 957 
Small IC50 Screening ~5% Hit rate 50 907 957 
Table A.1: 6 different MTb datasets were used with the above number of molecules in order to simulate different 
dataset types that may be used for machine learning are shown. 4 datasets were primary screening. Two different 
assays – resazurin and luciferase – were used, and a boolean discrimination of z-scores determined the hit selection 
for the large primary screens. Then, the 2 IC50 datasets were processed with a boolean discrimination to get similar 
hit rates as the large datasets. Finally, the best 957 molecules from the large primary screening were taken to create 
the small primary screening datasets, and a boolean discrimination matched the hitrate to the IC50 data. This 
directly shows the advantage of IC50 data over primary screening discriminations. This also shows the advantage 
of large datasets. The data was collected by Jeremy Woods in the Sacchettini Lab @ TAMU. 
